Use of Immunomodulators (Etanercept) in a Miniseries with Covid-19 Patients, to Decrease the Progress of Complications and Risks of Entry into Critical Care. Bibliography Review
Adán Oliveros-Ceballos1*, Janeth Gutiérrez-Segura2, Adrian Israel Ramirez-Mendoza3 and Bryan Adan Oliveros-Galeana4
Journal Title:Acta Scientific Women's Health
Objective: This study aims to describe the clinical results of a miniseries of 6 patients who presented characteristic COVID-19 symptoms and PCR positive, who were administered Etanercept, to avoid Cytokine release syndrome with the purpose of decreasing admission to the critical care unit. Design: This is a prospective, descriptive observational study. Patients and Methods: 6 patients with (SARS-CoV-2) COVID-19 symptoms were evaluated for the administration of the immunomodulator Etanercept 50 mg. Two groups were aligned: A) Mild: with fever, cough, images compatible with pneumonia, and gastrointestinal symptoms; B) Moderate: with fever, cough, images compatible with pneumonia, gastrointestinal symptoms and respiratory distress considered as L phenotype. Results: A total of 13 patients were identified with suspected infection of the virus (SARS-CoV-2) COVID-19, from which 6 patients accepted the administration of the immunomodulator Etanercept 50 mg (subcutaneous) in a single dose and protocol follow-up. From these 6 patients: 4 patients had fever, cough, headache and risk factors such as pregnancy and obesity; and 2 patients also presented respiratory distress considered as L phenotype. All 6 evolved to improvement. No patient was admitted to the critical intensive care unit and did not require invasive ventilatory support. Conclusion: In this miniseries, the administration of the Etanercept immunomodulator in patients with (SARS-CoV-2) from mild to moderate stage, improved the clinical evolution and reduced the risk of admission to the intensive care unit. However, more patients and more controlled and randomized studies are necessary to recommend immunomodulators.